Lisa Licitra

25PUBLICATIONS
215CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 23, 2026
Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

|Apr 01, 2026
Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer.

Sri Vemulamanda, Aditi Kothari, Loris De Cecco

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Sep 08, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.

Caroline Even, Kevin J Harrington, Erminia Massarelli

|Sep 03, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.

Jean Bourhis, Lisa F Licitra, Barbara Burtness

Pageof 5

Frequent Collaborators

9 joint publications

Stefano Cavalieri

8 joint publications

Laura Locati

8 joint publications

Robert I Haddad

7 joint publications

Kevin J Harrington